Overview
Balance Sheet
Cash Flow
Growth Analysis
2024
2023
2022
2021
2020
Profitability Metrics
Gross Margin
100.00%
Operating Margin
48.05%
Net Margin
21.77%
Efficiency Metrics
Revenue per Expense Ratio
1.92
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
28.61%
Income Tax Rate
23.11%
EPS
8.0500000000
Balance Sheet Analysis
Current Ratio
0.00
Cash Ratio
0.54
Working Capital
$-207.50B
Debt to Equity
2.54
Debt to Assets
23.15%
Equity Ratio
9.11%
Cash Flow Analysis
Operating Cash Flow Ratio
66.30%
Free Cash Flow Ratio
63.33%
CapEx to Revenue
2.97%
Dividends Paid
$2.63B
Stock Buybacks
$5.95B
Total Shareholder Returns
$8.58B
Cash Position Change
-5.76%
Key Takeaways (2024 FY)
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
14.71%
Net Income
47.35%
EPS
53.63%
Operating Income
25.44%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
6.30%
Operating Cash Flow
100.00%
Free Cash Flow
100.00%
Balance Sheet Health
Assets
-100.00%
Debt
-100.00%
Book Value per Share
7.12%
Inventory
0.00%
Shareholder Returns
Dividends per Share
-100.00%
Shares Outstanding
-2.27%
Long Term Trends
3Y Revenue/Share
15.47%
5Y Revenue/Share
51.05%
3Y Dividend/Share
-100.00%
5Y Dividend/Share
-100.00%